Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV.

Saved in:
Bibliographic Details
Title: Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV.
Authors: Mylvaganam GH; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.; Division of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA., Chea LS; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.; Division of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA., Tharp GK; Division of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA., Hicks S; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.; Division of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA., Velu V; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.; Division of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA., Iyer SS; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.; Division of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA., Deleage C; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland, USA., Estes JD; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland, USA., Bosinger SE; Division of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA., Freeman GJ; Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Ahmed R; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.; Division of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA., Amara RR; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.; Division of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Source: JCI insight [JCI Insight] 2018 Sep 20; Vol. 3 (18). Date of Electronic Publication: 2018 Sep 20 (Print Publication: 2018).
Publication Type: Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: eCollection Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2379-3708
DOI:10.1172/jci.insight.122940